Related references
Note: Only part of the references are listed.DNA damage-induced cell death is enhanced by progression through mitosis
Hanne Varmark et al.
CELL CYCLE (2011)
Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
Francesca Chiarini et al.
CANCER RESEARCH (2009)
Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome
Zhengping Zhuang et al.
CELL CYCLE (2009)
The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior
Yan Liu et al.
CELL CYCLE (2009)
Mutant p53 rescue and modulation of p53 redox state
Vladimir J. N. Bykov et al.
CELL CYCLE (2009)
Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence
Zoya N. Demidenko et al.
CELL CYCLE (2009)
The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells
Angelina V. Vaseva et al.
CELL CYCLE (2009)
Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation
Anne Fernandez-Vidal et al.
CELL CYCLE (2009)
Aging-suppressants Cellular senescence (hyperactivation) and its pharmacologic deceleration
Mikhail V. Blagosklonny
CELL CYCLE (2009)
The CML stem cell Evolution of the progenitor
Scott A. Stuart et al.
CELL CYCLE (2009)
At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence
Zoya N. Demidenko et al.
CELL CYCLE (2009)
Rapamycin decelerates cellular senescence
Zoya N. Demidenko et al.
CELL CYCLE (2009)
Specific activation of the p53 pathway by low dose actinomycin D A new route to p53 based cyclotherapy
Meng Ling Choong et al.
CELL CYCLE (2009)
Genomic instability en route to and from cancer stem cells
Linda Li et al.
CELL CYCLE (2009)
Targeting mTOR with rapamycin One dose does not fit all
David A. Foster et al.
CELL CYCLE (2009)
PIK3CA mutations in human solid tumors Role in sensitivity to various therapeutic approaches
Giovanni Ligresti et al.
CELL CYCLE (2009)
PI3K/mTORC1 activation in hamartoma syndromes Therapeutic prospects
Vera P. Krymskaya et al.
CELL CYCLE (2009)
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
N. Misaghian et al.
LEUKEMIA (2009)
Growth stimulation leads to cellular senescence when the cell cycle is blocked
Zoya N. Demidenko et al.
CELL CYCLE (2008)
Targeting prostate cancer based on signal transduction and cell cycle pathways
John T. Lee et al.
CELL CYCLE (2008)
BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death
Mark Wade et al.
CELL CYCLE (2008)
RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sindy Sohr et al.
CELL CYCLE (2008)
Phosphoinositide 3-kinase signaling overrides a G2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage
Dipali Nimbalkar et al.
CELL CYCLE (2008)
Cancer stem cells and survival pathways
Dolores Hambardzumyan et al.
CELL CYCLE (2008)
Resist or die FOXO transcription factors determine the cellular response to chemotherapy
Ana R. Gomes et al.
CELL CYCLE (2008)
Cancer and aging: More puzzles, more promises?
Mikhail V. Blagosklonny et al.
CELL CYCLE (2008)
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
Ramiro Paris et al.
CELL CYCLE (2008)
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Arkaitz Carracedo et al.
CELL CYCLE (2008)
Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation
Mingxuan Xia et al.
CELL CYCLE (2008)
The role of the PTEN/AKT pathway in NOTCH1-induced leukemia
Teresa Palomero et al.
CELL CYCLE (2008)
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
J. A. McCubrey et al.
LEUKEMIA (2008)
c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia
E. D. Lagadinou et al.
LEUKEMIA (2008)
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism
F. Chiarini et al.
LEUKEMIA (2008)
Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance
J. A. McCubrey et al.
LEUKEMIA (2008)
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
L. S. Steelman et al.
LEUKEMIA (2008)
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
L. S. Steelman et al.
ONCOGENE (2008)
Aging, stem cells, and mammalian target of rapamycin: A prospect of pharmacologic rejuvenation of aging stem cells
Mikhail V. Blagosklonny
REJUVENATION RESEARCH (2008)
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells
V. Papa et al.
LEUKEMIA (2008)
PI-PLC beta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes
M. Y. Follo et al.
LEUKEMIA (2008)
Program-like aging and mitochondria: Instead of random damage by free radicals
Mikhail V. Blagosklonny
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Cancer stem cell and cancer stemloids
Mikhail V. Blagosklonny
CANCER BIOLOGY & THERAPY (2007)
Dual inhibition of PI3K/Akt signaling and the DNA damage checkpoint in p53-deficient cells with strong survival signaling - Implications for cancer therapy
Andrzej Skladanowski et al.
CELL CYCLE (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts
P. L. Tazzari et al.
LEUKEMIA (2007)
Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells
F. E. Bertrand et al.
LEUKEMIA (2006)
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
A. M. Martelli et al.
LEUKEMIA (2006)
Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells
JG Shelton et al.
ONCOGENE (2003)
P21Cip1 induced by Raf is associated with increased Cdk4 activity in hematopoietic cells
FM Chang et al.
ONCOGENE (2001)
Share Paper
